Please login to the form below
Disarm Therapeutics
This page shows the latest Disarm Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Lilly buys biotech firm Disarm Therapeutics for $135m
Deal could eventually be worth up to $1.36bn. Eli Lilly is set to acquire private biotech company Disarm Therapeutics for an initial upfront payment of $135m, with a focus on ... Disarm’s focus is on the development of a new class of disease-modifying
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- My journey advancing the science in pulmonary hypertension
- NHS App to revolutionise digital health and care with major digital updates by 2023
- A new era for UK-Japanese scientific research relations
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Novartis announces positive phase 3 trial results for advanced oesophageal cancer
- Sanofi Global Health unveils new nonprofit Impact brand
- Pfizer announces commitment to achieve Net-Zero Standard by 2040
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- A creative awakening – how pharma is bringing innovation to the patient journey
- Behaviour change – a maze of decisions influenced by personal habits, experiences and intentions
- My journey advancing the science in pulmonary hypertension
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Novartis publishes final positive phase 3 results of Zolgensma in Nature Medicine
- Delivering content to fuel omnichannel engagement
PMHub
Say Communications
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
